CAS NO: | 1840942-14-4 |
包装 | 价格(元) |
500 μg | 电议 |
1mg | 电议 |
Cas No. | 1840942-14-4 |
别名 | C18 Ceramide-d7 |
化学名 | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-15,15,16,16,17,17,17-d7]-octadecanamide |
Canonical SMILES | OC[C@H](NC(CCCCCCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H] |
分子式 | C36H64D7NO3 |
分子量 | 573 |
溶解度 | DMF: 0.15 mg/ml |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | C18 Ceramide-d7 is intended for use as an internal standard for the quantification of C18 ceramide by GC- or LC-MS. C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.[1] Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.[2] It is selectively down-regulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.[3] Reference: |